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The IL-6-triggered positive feedback loop for NFkB
signaling (or the IL-6 amplifier/Inflammation ampli-
fier) was originally discovered as a synergistic-
activation signal that follows IL-17/IL-6 stimulation
in nonimmune cells. Subsequent results from
animal models have shown that the amplifier is
activated by stimulation of NFkB and STAT3
and induces chemokines and inflammation via an
NFkB loop. However, its role in human diseases is
unclear. Here, we combined two genome-wide
mouse screens with SNP-based disease association
studies, revealing 1,700 genes related to the IL-6
amplifier, 202 of which showed 492 indications of
association with ailments beyond autoimmune
diseases. We followed up on ErbB1 from our list.
Blocking ErbB1 signaling suppressed the IL-6 ampli-
fier, whereas the expression of epiregulin, an ErbB1
ligand, was higher in patients with inflammatory
diseases. These results indicate that the IL-6 ampli-
fier is indeed associated with human diseases and
disorders and that the identified genes may make
for potential therapeutic targets.
INTRODUCTION
IL-6 is thought to have an important role in the development of
autoimmune diseases and other inflammatory conditions (Awas-
thi and Kuchroo, 2009; Hirano, 1998, 2010; Nishihara et al., 2007;
O’Shea et al., 2002; Sakaguchi and Sakaguchi, 2005). It is also
one of the many cytokines induced by CD4+ T cells. In addition,
IL-6 is required for the development of Th17 cells, which are946 Cell Reports 3, 946–959, March 28, 2013 ª2013 The AuthorsIL-17-expressing activated CD4+ T cells (Bettelli et al., 2007;
Cua et al., 2003; Harrington et al., 2005; Park et al., 2005;
Veldhoen et al., 2006) that are strongly correlated with various
autoimmune models (Afzali et al., 2007; Bettelli et al., 2007;
Hirota et al., 2007; Iwakura and Ishigame, 2006; Ogura et al.,
2008). IL-6 signaling has been studied in various inflammatory
disease models including F759 mice, which express a mutant
variant of the IL-6 signaling transducer gp130, which enhances
STAT3 activation due to deficient SOCS3-mediated negative
feedback (Ohtani et al., 2000). As these mice age, they sponta-
neously develop an MHC class II-associated, IL-6-dependent,
tissue-specific joint disease (F759 arthritis) that resembles rheu-
matoid arthritis (Atsumi et al., 2002; Sawa et al., 2006). Further-
more, the development of F759 arthritis is mediated by the
excessive activation of IL-6 signaling in nonimmune, IL-7-
expressing tissue, which causes development of Th17 cells
(Hirano, 2010; Ogura et al., 2008; Sawa et al., 2006), suggesting
that the interaction between nonimmune tissue and immune
system plays a crucial role in some autoimmune diseases.
We identified the IL-6 amplifier/Inflammation amplifier as
a positive feedback loop for NFkB targets, including IL-6, in
type 1 collagen+ cells after stimulation with IL-17 and IL-6
(Ogura et al., 2008). The amplifier is induced by simultaneous
activation of NFkB and STAT3 and acts as a local chemokine
inducer to cause inflammation via a NFkB loop. Indeed, the
IL-6 amplifier is important for the development of autoimmune
disease in F759 arthritis and EAE, a multiple sclerosis model
(Arima et al., 2012; Murakami and Hirano, 2011; Murakami
et al., 2011; Ogura et al., 2008). Here, we considered whether
the IL-6 amplifier/Inflammation amplifier is also associated with
human disease.
Recent advances in mammalian RNAi and small hairpin RNA
(shRNA) technologies have made it possible to screen system-
atically for phenotypes that indicate inactive intracellular
signaling. We systemically screened, using an shRNA system
Figure 1. Scheme for Screening Positive Regulators of IL-6-Mediated Amplification and Inflammation
(A) Schematic of the primary screen. A BC1 mouse type 1 collagen+ cell line was cultured in 96-well plates and treated with a lentivirus that encoded shRNA
specific for candidate genes. The resulting BC1 cells were stimulated with human IL-6, soluble IL-6 receptor, and mouse IL-17. Mouse IL-6 concentrations in the
supernatant and cell survival were measured by ELISA and mitochondrial activity, respectively.
(B) Top: Mouse IL-6 expression in BC1 cells stimulated with various concentrations of human IL-6, human soluble IL-6 receptor, and mouse IL-17. Bottom:
Survival of BC1 cells transduced with control shRNA after stimulation with various concentrations of human IL-6, human soluble IL-6 receptor, and mouse IL-17.
(C and D) Candidate genes were selected based on two criteria: (i) expression of mouse IL-6, and (ii) cell survival. We selected shRNA that resulted in mouse IL-6
expression levels that were less than 35% the average IL-6 expression level in the 96-well plate. Cell survival was also evaluated based on mitochondrial activity
using TCO reagent (gray squares). Themean and SD for all BC1 cells were 1.88 and 0.08, respectively. The threshold value was therefore set at 1.88 0.08 = 1.8.
shRNA-screening results specific for 11 known genes in the IL-6 (C) and IL-17 (D) signaling pathways are shown.Mouse IL-6 expression levels are represented by
the black bars; relative cell survival by the gray squares. Black and white diamonds on the bottom denote shRNA that fulfilled the primary screening criteria by
more than 65% and inhibited IL-6 production by more than 50%, respectively. Dashed lines indicate thresholds (65%, 50%, and 1.8).
See also Figures S1, S2, S3, S4, S5, S6, and Table S10.and DNA microarray, for regulators and/or targets of IL-6 ampli-
fier activation and, thus, identify genes critical for chronic
inflammation. Because animal models do not always apply
to human diseases and disorders, we also considered SNP
analysis (Lander, 2011). Recent genome-wide association
studies (GWASs) have successfully associated SNPs with an
individual susceptibility to various pathologies. As a result,
we attempted to establish an approach that combines two
methods, systemic screening and GWAS, to identify which
genes may potentially regulate the development of human
diseases and disorders via inflammation, finding that the IL-6
amplifier/Inflammation amplifier is associated with a number
of diseases and disorders beyond autoimmune ones.RESULTS
In-Vitro High-Throughput Functional Screening of
Candidate Genes Involved in IL-6 Amplifier Activation
We first sought to identify which genes positively regulate IL-6
amplifier activation. To do this, we used a lentivirus expression
system to perform a genome-wide shRNA screen in BC1 murine
type 1 collagen+ cells. The expression of IL-6, which is also
synergistically induced by IL-6 and IL-17 (Ogura et al., 2008),
was used as a readout for the shRNA screen (Figure 1A). BC1
cells were stimulated with human IL-6 plus soluble IL-6 receptor
and IL-17. The expression level of mouse IL-6 and cell viability
were measured (Figure 1B).Cell Reports 3, 946–959, March 28, 2013 ª2013 The Authors 947
We tested about 65,500 lentivirus lines encoding shRNA,
which corresponds to approximately 16,000 mouse open
reading frames. We eliminated shRNA samples in which the
cell survival appeared impaired by using a threshold value
defined as the mean of the mitochondrial activity (cell viability)
for each shRNAminus one SD (1.88 0.08 = 1.80) because their
reduced IL-6 levels may have been the result of low cell numbers
in each well (see Experimental Procedures).
We then ranked candidate genes using the suppression rates
for IL-6 production. We selected the ranking system based on
the content rate of known signaling genes for the IL-6 and
IL-17 pathways. We selected the system described below,
which led to the inclusion of 11 known signaling genes for IL-6
and IL-17 pathways into the candidate list (Figures 1C and 1D).
In the first selection (genes ranked 0 in Tables S1 and S2, third
column from the left), at least three shRNAs of each gene sup-
pressed over 65% of IL-6 production. In the second selection
(those ranked 1), two shRNAs suppressed over 65%, and in
the third selection (those ranked 2), one shRNA suppressed
over 65%, and at least one other shRNA suppressed 50%. We
did not select genes that had at least two shRNA lentiviruses
with less than a 400% suppression in IL-6 expression regard-
less of the other selection criteria (see cells in second row from
the right side of Table S3). The screening identified a total of
1,289 candidate genes as positive regulators for the amplifier
(Table S2). Detailed data on the inhibition of IL-6 production by
a specific shRNA as well as cell viability are listed in Table S3.
We also considered the genes for which only one shRNA had
an inhibition rate >80% because this cutoff might be a good
candidate. This list contains 1,670 genes, and 425 overlap with
1,289 candidates (Table S4). Because 1,670 genes contained
less numbers of signaling genes for IL-6 and IL-17 pathways
(data not shown), we investigated the 1,289 candidates here.
However, we should not discard the genes that only one shRNA
had worked because experiments using MEF cells isolated from
mice without some of these genes showed that the gene-
deficient cells suppress IL-6 expression after IL-6 and IL-17
stimulation (data not shown).
We performed a second screen using 27 randomly selected
genes from those ranked 0–2. We established corresponding
gene-deficient BC1 cells using 54 shRNAs (2 per gene) and stim-
ulated them with IL-6 and/or IL-17. The shRNAs used here were
the same as those in the first screen. Although more than 90%
of shRNAs showed a statistically significant reduction (red
numbers in Table S5), 23 and 10 of the 54 randomly selected
shRNAs had an effect of more than 65% and 50%–65%
suppression (see cells with an asterisk [*] in third column of
Table S5), respectively, in response to IL-6 and IL-17. Thus, we
estimate the false-positive rate in this genome-wide screening
to be less than 40% (38.9%, 33 out of 54).
Moreover, we analyzed the mRNA expressions of two NFkB
targets, Il-6 and Cxcl1, both of which are hyperinduced after
IL-17 stimulation particularly in the presence of IL-6 stimulation,
and a STAT3 target, Socs3, which is induced by IL-6 stimulation,
by using shRNA for 25 genes (Gzmm and Pou4f1 were excluded
from the list of 27 because Gzmm shRNA #3 did not inhibit IL-6
expression after IL-6 and IL-17 stimulation, and Pou4f1 expres-
sion was too low to be detected by the real-time PCR detection948 Cell Reports 3, 946–959, March 28, 2013 ª2013 The Authorssystem.) (Figures S1, S2, S3, S4, S5, and S6C; Table S5).
We showed that at least one of the NFkB targets, Il-6 or Il-6
plus Cxcl1, was significantly suppressed in all 50 gene-deficient
cells, whereas Socs3 was suppressed in only 25 gene-deficient
cells (Figures S1, S2, S3, S4, S5, and S6C). We validated the
screening results using nine genes for 27 siRNA target
sequences (3 siRNA/gene) that were different from the shRNA
sequence. We selected the nine most suppressed siRNAs for
the target mRNA expression and found that six out of nine
(66.6%) significantly suppressed Il-6 mRNA expression after
IL-6 and IL-17 stimulation (Table S5). Thus, consistent with the
shRNA second screening results (Table S5), we also suggested
the false-positive rate in this genome-wide screening to be less
than 40%. These results suggest that the false-positive rate in
our first screen was relatively low. Therefore, at least half of the
1,289 candidate genes identified in functional screening should
be involved in IL-6 amplifier activation. However, only three out
of nine siRNAs in Table S5 suppressed Il-6 mRNA by more
than 50%, which is the cutoff in the first shRNA screening, which
was obtained from IL-6 ELISA. Although we hypothesize that the
knockdown efficiency of each target protein might vary due to
protein stability because of a transient effect of siRNA, it might
be possible that the false-positive rate of the shRNA screen
may be higher. Thus, wemight need to give attention to the over-
lapped gene lists, which obtain from combined results between
differential genome-wide screenings described below.
We compared the data of these 1,289 genes with those of
more than 1,000 randomly selected genes (see ‘‘randomly
selected control set (1,097)’’ in Table 1) to investigate whether
certain pathways and/or molecular characteristics are signifi-
cantly enriched in our list. The ingenuity systems pathway anal-
ysis (IPA)-based analysis demonstrated that only genes related
to pathways such as immune response and unclassified were
significantly enriched, whereas genes known to be related to
multiple biological processes were also present in the shRNA
list but insignificantly enriched (Tables 1 and S2). Thus, activation
of the IL-6 amplifier appears to be affected by multiple biological
processes and regulated by many genes.
Relationships between Candidate Genes that Are
Positive Regulators for IL-6 Amplifier Activation and
Human Diseases and Disorders
Among the 1,289 candidate genes, 1,177 have human homologs
(see blank cells in the column ‘‘mouse alone’’ of Table S2). Using
the Genetic Association Database (GAD) and two GWAS papers
by Consortium (2007) and Johnson and O’Donnell (2009), we
next investigated disease associations. We selected a total of
33 diseases and disorders including 8 autoimmune diseases,
3 metabolic syndromes, 6 neurodegenerative diseases, 4 psy-
chotic illnesses, and 12 other inflammatory diseases, finding
140 genes combined for a total of 334 positive associations
(Tables 2 and S1).
We then performed statistical comparison analysis using the
results of the functional shRNA screen and the control group
of more than 10,000 randomly selected genes (see the row
‘‘Mouse shRNA control’’ in Table 2). The number of expected
disease associations per gene including the control group is
shown in the column ‘‘Expected Disease Association’’ of Table 2.
Table 1. Summary of Biological Processes andCellular Localizations and Functions of the Candidate Genes for IL-6 Amplifier-Positive
Regulators, IL-6 Amplifier Targets in Mouse, and IL-6 Amplifier Targets in Human
Biological Processes Cellular Localizations and Functions 
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Randomly selected control set (1097) 51 213 181 190 71 94 65 243 251 145 1504 58 247 116 50 38 56 40 348 98 55 337 383 1826
Mouse shRNA screening 77 211 235 228 66 121 85 206 323 209 1761 76 287 147 63 33 75 37 289 100 82 306 365 1860
p values 0.076 0.026 0.133 0.407 0.079 0.244 0.251 0.000 0.108 0.020 0.260 0.442 0.260 0.353 0.098 0.223 0.143 0.000 0.150 0.079 0.000 0.000 
Mouse DNA array 57 111 67 90 34 74 36 120 140 71 800 55 142 55 50 13 28 9 181 56 14 183 133 919
p values 0.000 0.472 0.000 0.323 0.324 0.003 0.130 0.267 0.257 0.303 0.001 0.163 0.256 0.000 0.086 0.414 0.008 0.450 0.298 0.006 0.330 0.000 
Human DNA array 69 165 112 133 65 105 36 156 195 177 1213 64 171 65 56 5 30 16 269 45 27 298 257 1303
p values 0.002 0.332 0.008 0.085 0.223 0.008 0.000 0.006 0.327 0.000 0.037 0.042 0.007 0.041 0.000 0.031 0.007 0.263 0.001 0.015 0.081 0.003 
Mouse and human DNA array overlap 18 16 13 21 7 16 6 20 12 6 135 13 25 6 11 0 5 1 31 8 3 29 12 144
p values 0.000 0.408 0.353 0.055 0.285 0.001 0.357 0.429 0.025 0.045 0.000 0.092 0.139 0.001 0.039 0.397 0.110 0.226 0.472 0.258 0.306 0.000 
First, second, fourth, sixth, and eighth lines show gene numbers of the indicated pathway, molecular characteristics, and molecular localization in
control, mouse shRNA screening, mouse DNA microarray, human DNA microarray, and mouse and human DNA array overlaps, respectively. Third,
fifth, seventh, and ninth lines show p values for gene enrichment in mouse shRNA screening, mouse DNA microarray, human DNA microarray, and
mouse and human DNA array overlaps, respectively, when compared with over 1,000 control genes (‘‘control (1,097 genes)’’). Red-colored numbers
indicate statistically significant increases, whereas those with blue numbers show statistically significant decreases (p < 0.1). See also Tables S3, S4,
S5, and S10.Four of the five disease categories (all but psychotic illnesses)
were significantly enriched in the gene list (see Table 2,
summary). More specifically, genes relating to six autoimmune
diseases (rheumatoid arthritis, multiple sclerosis, celiac disease,
lupus, pancreatitis, and thyroiditis/Grave’s disease), three meta-
bolic syndromes (cardiovascular diseases/atherosclerosis/
systemic sclerosis, hypertension/blood pressure, and type 2
diabetes/NIDDM), four neurodegenerative diseases (Alzheimer’s
disease/hippocampal atrophy, neuropathy, ALS, and prion
disease), and nine other inflammatory diseases (atopy/
dermatitis/allergy, pulmonary disease/asthma/cystic fibrosis,
hepatitis, inflammatory bowel disease/colitis, vitiligo, periodonti-
tis, polyposis, stroke, and nephropathy/glomerulonephritis) were
significantly enriched (Table 2). These results strongly suggest
that the candidate genes positively involved in IL-6 amplifier acti-
vation are critical for the development of many human diseases
and disorders.
Relationships between Candidate Genes Induced after
IL-6 Amplifier Activation and Human Diseases and
Disorders
We hypothesized that target genes of the IL-6 amplifier could
also associate with various human diseases and disorders. We
employed microarray analysis to study these genes in type 1
collagen+ fibroblasts with or without IL-6 and IL-17 stimulation
(Table S6). We selected 576 target genes after performing the
experiment twice (Table S7) and ranked them based on their
increased level of expression 12 hr after stimulation (ranking
0–2 third column in Table S7). Indeed, among the 576 candidate
genes, 542 have human homologs (see blank cells in the fourth
column of Table S7). IPA-based analysis with over 1,000
randomly selected control genes showed that genes relatedto some pathways such as immune response, apoptosis, and
molecular characteristics such as extracellular space and
receptor binding were significantly enriched in the mouse micro-
array list (Tables 1 and S7).
GAD identified 70 of the 542 genes to have 202 positive asso-
ciations with various diseases and disorders (Tables 2 and S8).
We then performed statistical comparison analysis using these
results and the control set of over 10,000 randomly selected
genes (see the row ‘‘Mouse DNA array control’’ in Table 2). The
same four disease categories from the shRNA screening results
were significantly enriched in the microarray gene list (Table 2).
Moreover, genes related to six autoimmune diseases (type 1
diabetes/IDDM, Crohn’s disease, rheumatoid arthritis, lupus,
pancreatitis, and thryoiditis/Grave’s disease), three metabolic
syndromes (cardiovascular diseases/atherosclerosis/systemic
sclerosis, hypertension/blood pressure, and type 2 diabetes/
NIDDM), two neurodegenerative diseases (Alzheimer’s disease/
hippocampal atrophy and Parkinson’s disease), and seven
other inflammatory diseases (pulmonary disease/asthma/cystic
fibrosis, hepatitis, inflammatory bowel disease/colitis, sepsis,
psoriasis/scleroderma, stroke, and nephropathy/glomerulone-
phritis) were significantly enriched (Table 2).
We showed that human type 1 collagen+ cell lines synergisti-
cally express Il-6 after IL-6 and IL-17 stimulation (Figure S7A).
We employed human microarray analysis to study the target
genes directly in a human type 1 collagen+ synovial fibroblast
line with or without IL-6 and IL-17 stimulation. We selected 885
target gene candidates after performing the experiment twice
(Table S9) and ranked them based on their increased level of
expression 12 hr after stimulation (ranking 0–2, third column in
Table S7). IPA-based analysis with over 1,000 randomly selected
control genes showed that genes related to pathways such asCell Reports 3, 946–959, March 28, 2013 ª2013 The Authors 949
Table 2. Summary of Associations between Human Diseases and Disorders and Candidate Genes for IL-6 Amplifier-Positive
Regulators and for IL-6 Amplifier Targets in Mouse and Human Systems
 N
um
be
r O
f S
el
ec
te
d 
G
en
es
 
 N
um
be
r O
f D
is
ea
se
 A
ss
oc
ia
tio
ns
 
 E
xp
ec
te
d 
D
is
ea
se
 A
ss
oc
ia
tio
ns
 
Autoimmune Diseases 
Metabolic
Syndromes Neurodegenerative Diseases Psychotic Illnesses Other Inflammatory Diseases Summary
 T
yp
e 
1 
D
ia
be
te
s/
ID
D
M
 
 C
ro
hn
’s
 D
is
ea
se
 
 R
he
um
at
oi
d 
A
rth
rit
is
 
 M
ul
tip
le
 S
cl
er
os
is
 
 C
el
ia
c 
D
is
ea
se
 
 L
up
us
 
3
DQ
FU
HD
WLW
LV

7
K\
UR
LG
LWL
V
*
UD
YH

V
'
LV
HD
VH

 C
ar
di
ov
as
cu
la
r D
is
ea
se
s/
 A
th
er
os
cl
er
os
is
/S
ys
te
m
ic
 S
cl
er
os
is
 
 H
yp
er
te
ns
io
n/
B
lo
od
 P
re
ss
ur
e 
 T
yp
e 
2 
D
ia
be
te
s/
N
ID
D
M
 
 A
lz
he
im
er
’s
 D
is
ea
se
/H
ip
po
ca
m
pa
l A
tro
ph
y 
 P
ar
ki
ns
on
’s
 D
is
ea
se
 
 N
eu
ro
pa
th
y 
 A
m
yo
tro
pi
c 
La
te
ra
l S
cr
er
os
is
 
 P
rio
n 
D
is
ea
se
 
 E
pi
le
ps
y 
 S
ch
iz
op
hr
en
ia
 
 B
ip
ol
ar
 D
is
or
de
r 
 D
ep
re
ss
io
n 
 C
og
ni
tiv
e 
P
er
fo
rm
an
ce
 
D
WR
S\
'
HU
P
DW
LWL
V
$
OOH
UJ
\
 P
ul
m
on
ar
y 
D
is
ea
se
/A
st
hm
a/
C
ys
tic
 F
ib
ro
si
s 
 H
ep
at
iti
s 
 I
nf
la
m
m
at
or
y 
B
ow
el
 D
is
ea
se
/C
ol
iti
s 
 S
ep
si
s 
 V
iti
lig
o 
 P
er
io
do
nt
iti
s 
 P
ol
yp
os
is
 
 P
so
ria
si
s/
S
cl
er
od
er
m
a 
 S
tro
ke
 
 N
ep
hr
op
at
hy
/G
lo
m
er
ul
on
ep
hr
iti
s 
 G
V
H
D
/T
ra
ns
pl
an
ta
tio
n 
C
om
pl
ic
at
io
n 
 A
ut
oi
m
m
un
e 
D
is
ea
se
s 
 M
et
ab
ol
ic
 S
yn
dr
om
e 
 N
eu
ro
de
ge
ne
ra
tiv
e 
D
is
ea
se
s 
 P
sy
ch
ot
ic
 Il
ln
es
se
s 
 O
th
er
 In
fla
m
m
at
or
y 
D
is
ea
se
s 
Mouse shRNA screening 1177 334 0.284  13 7 15 17 8 17 4 5 33 25 27 16 4 2 6 1 1 16 5 7 2 12 28 9 9 2 5 7 2 4 7 16 2 86 85 30 30 310  
Mouse shRNA control 12226 1813 0.148  105 60 86 64 45 67 10 24 168 187 211 108 61 0 16 0 10 125 43 48 35 33 128 3 45 17 3 22 0 35 21 27 10 461 566 195 251 344 
p values 0.000 0.195 0.315 0.015 0.000 0.052 0.000 0.004 0.054 0.000 0.059 0.080 0.052 0.227 0.000 0.001 0.001 0.486 0.140 0.344 0.150 0.234 0.000 0.000 0.000 0.020 0.394 0.000 0.002 0.000 0.372 0.001 0.000 0.167 0.000 0.000 0.007 0.128 0.000 
Mouse DNA array 542 202 0.373  14 10 11 5 3 9 2 4 23 18 20 8 6 0 1 0 0 5 3 2 1 3 19 5 5 3 0 2 0 6 5 8 1 58 61 15 11 75  
Mouse DNA array control 11694 1814 0.155  99 57 86 63 41 70 11 23 172 185 203 107 55 2 18 1 10 127 45 48 29 40 127 8 42 15 7 25 2 32 23 31 12 450 560 193 249 364 
p values 0.000 0.000 0.000 0.000 0.120 0.220 0.001 0.027 0.004 0.000 0.001 0.000 0.093 0.020 0.381 0.430 0.415 0.248 0.360 0.270 0.441 0.385 0.208 0.000 0.000 0.019 0.006 0.285 0.226 0.381 0.000 0.000 0.000 0.284 0.000 0.000 0.025 0.438 0.000 
Human DNA array 885 265 0.299  12 9 15 8 10 12 4 6 33 14 22 15 5 0 1 0 2 7 2 2 4 7 20 7 12 4 2 3 0 11 6 6 4 09 69 23 15 21 8  
Human DNA array control 11715 1772 0.151  92 55 82 66 40 67 10 21 174 187 198 99 54 2 18 1 11 122 45 46 33 37 122 8 42 16 8 22 2 29 20 35 8 433 559 185 246 349 
p values 0.000 0.035 0.014 0.001 0.000 0.000 0.002 0.001 0.001 0.000 0.487 0.041 0.005 0.331 0.349 0.382 0.392 0.119 0.238 0.229 0.219 0.184 0.011 0.000 0.000 0.000 0.012 0.054 0.165 0.349 0.000 0.001 0.028 0.000 0.000 0.000 0.011 0.208 0.000 
Mouse and Human array overlap 87 71 0.816  4 3 3 3 2 3 1 1 9 4 7 3 3 0 0 0 0 1 1 0 0 1 5 5 2 1 0 0 0 2 3 3 1 20 20 6 2 32  
Array overlap control 11743 1937 0.165  107 64 94 65 42 76 12 26 183 197 213 110 58 2 19 1 10 131 47 51 30 43 140 8 45 18 7 27 2 36 26 35 12 486 593 200 259 399 
p values 0.000 0.000 0.000 0.003 0.000 0.002 0.001 0.002 0.035 0.000 0.018 0.000 0.008 0.000 0.452 0.354 0.466 0.393 0.488 0.137 0.269 0.319 0.116 0.000 0.000 0.002 0.010 0.410 0.327 0.452 0.001 0.000 0.000 0.002 0.000 0.000 0.000 0.477 0.000 
The first, fourth, seventh, and tenth lines show the number and percentage of genes with indicated disease/disorder associations based on the GAD
website for our mouse shRNA screening, mouse DNA microarray, human DNA microarray, and mouse and human DNA array overlaps, respectively.
The 3rd, 6th, 9th, and 12th lines show p values for gene enrichment in the mouse shRNA screening, mouse DNAmicroarray, human DNAmicroarray, and
mouse and human DNA array overlaps, respectively, when compared with over 10,000 control genes. Red numbers indicate statistical differences
(p < 0.1). See also Tables S1, S2, S3, S4, S5, and S10.immune response, apoptosis, and unclassified, molecular char-
acteristics such as extracellular space and receptor binding, and
nucleus were significantly enriched in the human microarray list
(Tables 1 and S7). GAD identified 94 of the 885 genes as having
265 positive associations with various diseases and disorders
(Tables 2 and S8). We then performed statistical comparison
analysis using these results and the control set of over 10,000
randomly selected genes (see the row ‘‘Human DNA array
control’’ in Table 2). Once again, the same four disease cate-
gories were significantly enriched in the human microarray
gene list (Table 2). Moreover, genes related to eight autoimmune
diseases (type 1 diabetes/IDDM, Crohn’s disease, rheumatoid
arthritis, multiple sclerosis, celiac disease, lupus, pancreatitis,
and thryoiditis/Grave’s disease), two metabolic syndromes
(cardiovascular diseases/atherosclerosis/systemic sclerosis
and type 2 diabetes/NIDDM), one neurodegenerative disease
(Alzheimer’s disease/hippocampal atrophy), and ten other
inflammatory diseases (atopy/dermatitis/allergy, pulmonary
disease/asthma/cystic fibrosis, hepatitis, inflammatory bowel
disease/colitis, sepsis, vitiligo, psoriasis/scleroderma, stroke,
nephropathy/glomerulonephritis, and GVHD/transplantation
complications) were significantly enriched (Tables 2 and S8).
Thus, we confirmed the involvement of the IL-6 amplifier in the
development of many human diseases and disorders by human
microarray experiments.
Additionally, in the microarray studies, we found 87 overlaps
between the 542 mouse and 885 human targets and 16 overlaps
between the 70 mouse and 94 human genes associated with
human diseases. We performed IPA-based analysis of the 87
genes with over 1,000 randomly selected control genes and950 Cell Reports 3, 946–959, March 28, 2013 ª2013 The Authorsshowed that the genes among them related to the pathways,
immune response, signal transduction, apoptosis, andmolecular
characteristics such as extracellular space, plasma membrane,
and receptor binding were significantly enriched (Tables 1 and
S7). GAD identified 16of the 87 genes as having 71 positive asso-
ciations with various diseases and disorders (Tables 2 and S8).
We then performed statistical comparison analysis using these
results and the control set of over 10,000 randomly selected
genes (see the row ‘‘Array overlap control’’ in Table 2). Once
again, the aforementioned four disease categories were signifi-
cantly enriched in the overlaps (Tables 2 and S8). Moreover,
genes related to eight autoimmune diseases (type 1 diabetes/
IDDM, Crohn’s disease, rheumatoid arthritis, multiple sclerosis,
celiac disease, lupus, pancreatitis, and thryoiditis/Grave’s
disease), three metabolic syndromes (cardiovascular diseases/
atherosclerosis/systemic sclerosis, hypertension/blood pres-
sure, and type 2 diabetes/NIDDM), two neurodegenerative
diseases (Alzheimer’s disease/hippocampal atrophy and
Parkinson’s disease), and eight other inflammatory diseases
(pulmonary disease/asthma/cystic fibrosis, hepatitis, inflamma-
tory bowel disease/colitis, sepsis, psoriasis/scleroderma, stroke,
nephropathy/glomerulonephritis, and GVHD/transplantation
complications) were significantly enriched (Tables 2 and S8). We
hypothesize that these overlapsmight be critical for the develop-
ment of diseases and disorders via IL-6 amplifier activation.
The Epiregulin-ErbB1 Pathway Plays a Role in IL-6
Amplifier Activation
To further establish the importance of the amplifier activation in
human diseases and disorders, we sought to select specific
Figure 2. The Epiregulin-ErbB1 Pathway Activates the IL-6 Amplifier In Vitro
(A) IL-6 amplifier activation was suppressed in the absence of FBS. BC1 cells were stimulated with human IL-6 plus soluble IL-6 receptor and/or IL-17 for 24 hr in
the absence or presence of 10% FBS. Gray dots indicate cell survival values monitored by TCO reagent. Left: Culture supernatants were collected and assessed
using an ELISA specific for mouse IL-6. Cell survival was also evaluated based onmitochondrial activity (gray squares; all points were above the threshold value).
Right: Il-6 mRNA expression 3 hr after stimulation was evaluated using real-time PCR.
(B) BC1 cells were stimulated with human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS for 3 hr. Epiregulin (Ereg) expression was then
evaluated using real-time PCR.
(C) BC1 cells were stimulated with human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS for 48 hr with or without EGF, another ErbB1 ligand.
Culture supernatants were collected and assessed using an ELISA specific for epiregulin.
(D) BC1 cells were stimulated with epiregulin in the absence of FBS for 3 hr. Epiregulin (Ereg) expression was evaluated using real-time PCR.
(E) BC1 cells were stimulated with human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS for 3 hr. ErbB1 (Egfr) expression was then evaluated
using real-time PCR.
(F) BC1 cells were stimulated with human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS for 24 hr with or without various concentrations of
epiregulin. Culture supernatants were collected and assessed using ELISA specific for IL-6.
(G–I) Il-6 (G),Ccl20 (H), and IkBz (I) mRNA expressions in BC1 cells 3 hr (G andH) or 1 hr (I) after stimulation with human IL-6 plus soluble IL-6 receptor and/or IL-17
in the absence of FBS with or without epiregulin were evaluated using real-time PCR.
(J) BC1 cells were treated with a lentivirus encoding shRNA specific for epiregulin (Ereg) and cultured in the presence of puromycin. The resulting cells were
stimulatedwith human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS for 48 hr. Culture supernatants were collected and assessed using ELISA
specific for mouse IL-6.
Mean scores ± SD are shown. p values were calculated using Student’s t tests. * and #, p < 0.05; ** and ##, p < 0.01; ***p < 0.001.
See also Figure S7 and Table S10.molecules from the aforementioned genes. We targeted the
ErbB1 pathway because (i) soluble molecule concentrations are
relatively easy to measure; (ii) ErbB1 and its ligands associate
withdiseasesanddisorders likeSLE, asthma, andcardiovascular
diseases; and (iii) ErbB1 is included in theeight overlappinggenes
that are associated with human diseases and disorders and
found in the both our shRNA screen and mouse DNA array lists.
We then investigated IL-6 expression in the absence of fetal
bovine serum (FBS), a rich source of ErbB1 ligands. Indeed,
IL-6 expression was significantly reduced in these cultures
despite stimulation with IL-6 and/or IL-17 (Figure 2A). Epiregulin,
an ErbB1 ligand, was synergistically expressed after IL-6 and
IL-17 stimulation, particularly in the presence of EGF (Figures
2B, 2C, and S7). Furthermore, Ereg (that encodes epiregulin)
mRNA expression was induced in the presence of epiregulin(Figures 2D and S7C), and IL-6 stimulation increased ErbB1
(Egfr) expression (Figure 2E). Importantly, epiregulin enhanced
the expression of IL-6 and other targets after IL-6 and IL-17
stimulation (Figures 2F–2I and S7), whereas Ereg deficiency by
shRNA decreased it (Figure 2J; data not shown). Thus, we
concluded that an epiregulin-ErbB1 pathway is involved in IL-6
amplifier activation.
It is important to understand how the epiregulin pathway
affects NFkB and/or STAT3 signaling. The phosphorylations of
Akt, p65, and ERK1/ERK2 increased after epiregulin stimulation
in the presence of IL-6 and IL-17 (Figure 3A). NFkB reporter
activity also increased after epiregulin stimulation (Figure 3B),
whereas a PI3K inhibitor, LY294002, but not a MEK inhibitor,
suppressed it (Figure 3C; data not shown), suggesting that
epiregulin enhances the PI3K-NFkB pathway. Consistent withCell Reports 3, 946–959, March 28, 2013 ª2013 The Authors 951
Figure 3. The Epiregulin Signal Enhances NFkB Activation via the PI3K a Pathway
(A) MEF cells were stimulated with epiregulin in the presence or absence of IL-6 and IL-17 and then investigated for the phosphorylation of Akt, p65, STAT3, and
ERK1/ERK2.
(B) HeLa cells were stimulated with epiregulin in the presence or absence of IL-17 and then investigated for NFkB reporter activity using a 53NFkB-luc construct.
(C) BC1 cells were stimulated with epiregulin in the presence or absence of LY294002 and then investigated for NFkB reporter activity using a 53 NFkB-luc
construct.
(D) IKKa- and IKKg-deficient MEF cells as well as wild-type MEF cells (WT) were stimulated with epiregulin (100 ng/ml) in the presence or absence of human IL-6
plus soluble IL-6 receptor and/or IL-17 for 12 hr. Culture supernatants were collected and assessed using an ELISA specific for mouse IL-6.
(E and F) BC1 cells were stimulated with human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS with or without epiregulin and various
concentrations of PIK75 (E) or TGX221 (F) for 24 hr. Cell survival was also evaluated based on mitochondrial activity. Culture supernatants were collected and
assessed using an ELISA specific for mouse IL-6.
(G and H) (G) BC1 cells were treated with a lentivirus encoding shRNA specific for Pik3ca and stimulated with epiregulin (100 ng/ml) in the presence or absence of
human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS for 24 hr. Culture supernatants were collected and assessed using an ELISA specific for
mouse IL-6. (H) Pik3ca expression was also evaluated using real-time PCR.
Mean scores ± SD are shown. p Values were calculated using Student’s t tests. *p < 0.05; **p < 0.01; ***p < 0.001; NS, not significant.
See also Figure S9 and Table S10.this, deficiencies in IKKa or IKKg as well as a PI3K a inhibitor
diminished the epiregulin-mediated enhancement, whereas a
PI3K b inhibitor did not (Figures 3D–3F). Additionally, a deficiency
of PI3K a suppressed the epiregulin-mediated enhancement of
IL-6 expression (Figures 3G and 3H). Thus, we show that the epi-
regulin signal enhances NFkB activation via the PI3K a pathway.952 Cell Reports 3, 946–959, March 28, 2013 ª2013 The AuthorsThe Epiregulin-ErbB1 Pathway Has a Role in
Autoimmune Disease Models
We have shown that F759 arthritis is mediated nonhemopoieti-
cally, particularly in type 1 collagen+ cells based on bone
marrow transplantation and a tissue-specific-deficient system
(Murakami et al., 2011; Ogura et al., 2008; Sawa et al., 2006).
Direct joint injections of IL-6 and IL-17 with a minimummodifica-
tion of hemopoietic cells induced arthritis within 2 weeks in
amanner dependent on the amplifier (Murakami et al., 2011). Co-
injection of a lentivirus encoding shRNA for Stat3 or Rela (NFkB
p65) in combination with IL-6 and IL-17 significantly suppressed
the disease (Murakami et al., 2011). We employed this method
and showed that joint injections of these cytokines induce Ereg
as well as Il-6 expression in the joints (Figure 4A). On the other
hand, joint injections of lentiviruses having Ereg- or ErbB1
(Egfr)-shRNA suppressed these expressions (Figure 4A) as well
as the development of F759 arthritis (Figures 4B and 4C). Joint
injections of an anti-epiregulin antibody or ErbB1 tyrosine kinase
inhibitors also suppressed the development of F759 arthritis
(Figures 4D–4G), a result confirmed by histology (Figure 4H).
These results too suggest that the epiregulin-ErbB1 pathway is
involved in the activation of the IL-6 amplifier, leading to cyto-
kine-induced arthritis. Moreover, systemic administration of an
ErbB1 tyrosine kinase inhibitor significantly suppressed the
development of EAE (Figure 4I) and decreased the number of
infiltrating cells in the spinal cord (Figure 4J). Together, these
results support the idea that the epiregulin-ErbB1 pathway
contributes to the pathogenesis of autoimmune disease models
most likely via the IL-6 amplifier.
Possible Epiregulin-ErbB1 Pathway Involvement in
Human IL-6 Amplifier Activation
Human type 1 collagen+ cells (Igarashi et al., 2010) also showed
enhanced expression of IL-6 after IL-6 and IL-17 treatment.
Additionally, epiregulin increased Il-6 expression in the presence
of IL-6 and IL-17, whereas an ErbB1 inhibitor suppressed it
(Figures 5A and 5B). Ereg was synergistically expressed in
human cells in response to IL-6 and IL-17 or itself (Figure 5C).
These results demonstrate that epiregulin contributes to the
amplifier activation in human cells in vitro.
We then evaluated whether epiregulin concentrations were
elevated in patients with rheumatoid arthritis, atherosclerosis,
and multiple sclerosis. Serum from patients suffering from one
of these diseases contained higher concentrations of epiregulin
compared to control subjects (Figures 5D–5F), consistent with
epiregulin being involved in inflammatory diseases in mice
through activation of the amplifier. Additionally, IL-6 concentra-
tions increased in serum from patients suffering from these
diseases (Figure S8; data not shown). These results too suggest
that the epiregulin-ErbB1 pathway contributes to the activation
of the IL-6 amplifier and has a role in the pathogenesis of various
human diseases and disorders.
DISCUSSION
Using two mouse genome-wide screens, we here identified
about 1,700 genes with human homologs that have a role in
IL-6 amplifier/Inflammation amplifier activation or intensity.
Because (1) many known IL-6 and IL-17 pathway positive regu-
lators were selected in the shRNA screen list, (2) there was high
reproducibility between the first and second functional screen-
ings, (3) of the low false-positive rates in the functional screening,
and (4) of the resemblances of the disease association patterns
between the shRNA screening and the DNA microarray screen-ings (humans and mice), we concluded that our genome-wide
screening systems were sound. Following comparisons with
GWAS results, we found that among the 1,700 screened genes,
202 genes (140 from the shRNA screen and 70 genes from the
DNAmicroarray analysis; with the following 8 genes overlapping:
ErbB1 [Egfr], Il-6, Pde4b, Ptgs2, Serpine1, Slit2, Socs2, and
Stat3) showed over 490 indications of association not only with
autoimmune diseases but also with metabolic syndromes,
neurodegenerative diseases, and other inflammatory diseases.
Furthermore, we showed that the epiregulin-ErbB1 pathway is
involved in the development of autoimmune disease models.
Moreover, the epiregulin-ErbB1 pathway enhanced the amplifier
in human nonimmune cells, and the epiregulin concentration in
serumwas highest in patients with inflammatory diseases. These
results suggest that IL-6 amplifier activation has an important
role in human diseases and disorders by regulating chronic
inflammation steps. Thus, we extended our previous conclusion
about the IL-6 amplifier being critical to the development of
chronic inflammation in mice to humans.
The IL-6 amplifier is a local chemokine inducer that induces
inflammation via an accumulation of various immune cells.
Therefore, it is reasonable that amplifier-related genes have
many disease associations because inflammation is a general
process that disturbs function in affected tissues. However,
genes from psychotic illnesses were not significantly enriched
in the IL-6 amplifier-related genes, which may indicate that
they are relatively unaffected by inflammation. Strong associa-
tions were found between IL-6 amplifier-related genes and
12 diseases: rheumatoid arthritis, lupus, pancreatitis, thyroiditis/
Grave’s diseases, cardiovascular diseases/atherosclerosis/
systemic sclerosis, type 2 diabetes/NIDDM, Alzheimer’s dis-
ease/hippocampal atrophy, pulmonary disease/asthma/cystic
fibrosis, hepatitis, inflammatory bowel disease/colitis, stroke,
and nephropathy/glomerulonephritis (see Table 2). We propose
that these 12 diseases could be candidates for the next clinical
trial of blockers for IL-6 and IL-17. In fact, anti-IL-6R antibody
has already been used against rheumatoid arthritis. Additionally,
it is possible that the positive regulator candidates from the
shRNA screen are involved in either the NFkB or STAT3 signaling
pathways or both because the amplifier is a synergy between
STAT3 and NFkB. Therefore, targets of the amplifier, which may
act as inflammation regulators, could be potential therapeutic
targets.
We found that several of the genes associated with human
diseases in our screening lists are known to control NFkB or
STAT3 activity. Such genes include Cckbr (Ferrand et al.,
2005), Ets1 (Thomas et al., 1997), Irak1 (Song et al., 2006),
Pde4 (Schmitz et al., 2007), Pla2g1b (Jo et al., 2004), Pou2af1
(Wolf et al., 1998), and Zbp1 (Kaiser et al., 2008). Furthermore,
we identified a number of genes that had previously unknown
function to be necessary for NFkB- and/or STAT3-mediated
signal transduction (data not shown). Interestingly, human
disease-linked NFkB and/or STAT3-driven genes such as Mthfr
(Pickell et al., 2005), Ptgs2 (D’Acquisto et al., 1997; Kojima et al.,
2000), and Vegfa (Adachi et al., 2006; Rojo et al., 2004) were
required for IL-6 amplifier activation according to our functional
screening, suggesting a possible positive feedback mechanism
of IL-6 amplifier activation through these molecules. TheseCell Reports 3, 946–959, March 28, 2013 ª2013 The Authors 953
Figure 4. Epiregulin-ErbB1 Signaling Triggers Autoimmune Diseases in Mouse Models
(A) IL-6 and IL-17 on days 6, 7, and 8 were injected into the joints of F759 mice in the presence or absence of joint injections of lentivirus encoding shRNA specific
for ErbB1 (Egfr) (n = 6), Ereg (n = 6), or a nontarget sequence (n = 6) on days 0, 2, and 4 followed by analysis of epiregulin and IL-6 expression in joint synovial
tissues on day 15.
(B) Clinical arthritis scores from the left legs of F759mice after left leg joint injections of 0.1 mg IL-17 and IL-6, respectively, on days 6, 7, and 8 and joint injections of
lentivirus encoding shRNA specific for ErbB1 (Egfr) (open squares, open triangles, and crosses; n = 3), NFkB p65 (Rela) (asterisks; n = 3), or a nontarget sequence
(diamonds; n = 3) on days 0, 2, and 4.
(C) Clinical arthritis scores from the left legs of F759 mice after left leg joint injections of 0.1 mg IL-17 and IL-6, respectively, on days 6, 7, and 8 and
joint injections of a lentivirus encoding shRNA specific for epiregulin (Ereg) (crosses, asterisks, and open circles; n = 3), NFkB p65 (Rela) (open triangles; n = 3),
or a nontarget sequence (squares; n = 3) on days 0, 2, and 4 and those from the left legs of F759 mice after left leg joint injections of saline alone (filled
diamonds, n = 3).
(D) Clinical arthritis scores from the left legs of F759mice after left leg joint injections of 0.1 mg IL-17 and IL-6, respectively, on days 0, 1, and 2 and joint injections of
anti-epiregulin antibodies (1 mg) on days 0–23 (open squares, n = 3) and from the left legs of F759 mice after left leg joint injections of IL-17, IL-6, and control IgG
(open circles, n = 3), or saline (open triangles, n = 3).
(E) Clinical arthritis scores from the left legs of F759 mice after left leg joint injections of 0.1 mg IL-17 and IL-6, respectively, on days 0, 1, and 2 and PD153035
(10 mg) on days 0–23 (triangles, n = 5) and from the left legs of F759 mice after left leg joint injections of IL-17, IL-6, and DMSO (squares, n = 5), or injections of
DMSO only (diamonds, n = 5).
(F) Clinical arthritis scores from the left legs of F759 mice after left leg joint injections of 0.1 mg IL-17 and IL-6, respectively, on days 0, 1, and 2 and PD168393
(10 mg) on days 0–24 (triangles, n = 5) and from the left legs of F759 mice after left leg joint injections of IL-17, IL-6, and DMSO (squares, n = 5), or injections of
DMSO only (diamonds, n = 5).
(G) Clinical arthritis scores from the left legs of F759mice after left leg joint injections of 0.1mg IL-17 and IL-6, respectively, on days 0, 1, and 2 andgefitinib (10 mg) on
days 0–22 (triangles, n = 4) and from the left legs of F759mice after left leg joint injections of IL-17, IL-6, andDMSO (squares, n = 4), or DMSOonly (diamonds, n = 4).
(H) Ankle joints from each mouse in (D) were fixed and embedded in paraffin. Histological analysis was performed using sections stained with hematoxylin-eosin.
These experiments were performed at least three times independently; representative data are shown.
(I) WTmice (2 months old) were intravenously injected with Th17 cells fromWTmice with EAE and intraperitoneally injected with gefitinib (open squares, n = 5) or
DMSO (open diamonds, n = 5) on days 0–6.
(J)WTmice (2monthsold)were intravenously injectedwith Th17 cells fromWTmicewith EAE and intraperitoneally injectedwith gefitinib (closedbars, n = 5) orDMSO
(open bars, n = 5) on days 0–6. Mononuclear cells from the spinal cords of Th17-transferred C57BL/6 mice were isolated on day 13. The resulting cell populations
(legend continued on next page)
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Figure 5. Epiregulin-ErbB1 Signaling Is Involved in Activation of the Human IL-6 Amplifier
(A) Human synovial cell lines were stimulated for 3 hr with human IL-6 plus soluble IL-6 receptor and/or IL-17 in the absence of FBS with or without epiregulin
(100 ng/ml). Il-6 expression in the resulting cells was evaluated using real-time PCR.
(B) Human synovial cells were stimulated for 3 hr with human IL-6 plus soluble IL-6 receptor and/or IL-17 in the presence of FBS with or without PD153035
(10 mg/ml). Il-6 expression in the resulting cells was evaluated using real-time PCR.
(C) Human synovial cells were stimulated with human IL-6 plus soluble IL-6 receptor and/or IL-17 or epiregulin in the absence of FBS for 3 hr. Ereg expression in
the resulting cells was evaluated using real-time PCR.
(D–F) Serumepiregulin concentrations in patients with (D) rheumatoid arthritis (n = 11), (E) atherosclerosis (n = 50), and (F)multiple sclerosis (n = 21) comparedwith
healthy-aged, sex-matched subjects (rheumatoid arthritis, n = 26; atherosclerosis n = 64; multiple sclerosis, n = 15).
Mean scores ± SD are shown. p values were calculated using Student’s t tests (* and #, p < 0.05; **p < 0.01; ***p < 0.001).
Related to Figures S7, S8, and Table S10.results strengthen the significance of the synergy between NFkB
and STAT3 molecules in human diseases and highlight the
amplifier as a fundamental mechanism for enhancing inflamma-
tion through synergistic activation of these two critical transcrip-were counted and stimulated in vitro with MOG peptide and bone marrow-derived
IFN-g levels were examined. CD4+IL-17+ and CD4+IFN-g T cells from Th17-transfe
CD4+IL-17+ and CD4+IFN-g+ T cells in spinal cords was significantly lower in the r
Mean scores ± SEM are shown. p Values were calculated using Student’s t testtion factors in nonimmune cells followed by a NFkB loop. We
selected one gene, ErbB1 (Egfr), from our gene list as a represen-
tative gene and analyzed its role in the development of inflamma-
tory diseases. We demonstrated that NFkB activation viadendritic cells. Twenty-four hours after in vitro stimulation, intracellular IL-17 and
rred C57BL/6 mice treated with gefitinib or vehicle were counted. The number of
ecipients treated with gefitinib than in those treated with DMSO.
s (* and #, p < 0.05; ** and ##, p < 0.01; ***p < 0.001). See also Table S10.
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epiregulin-ErbB1 signaling is involved in the development of
autoimmune diseases, and serum epiregulin concentrations
increase in patients suffering from rheumatoid arthritis, multiple
sclerosis, and atherosclerosis. Furthermore, we have identified
over 30 genes from our genome-wide screening lists that are
involved in the NFkB and/or STAT3 pathway and enhance IL-6
amplifier activation and the subsequent development of autoim-
mune diseases (data not shown). All these observations support
the notion that the genes identified here are candidate regulators
and/or targets of the IL-6 amplifier/Inflammation amplifier.
Curiously, Il-4ra and Jak3 appeared in Table S3 because
these are representative of IL-4. We confirmed via the second
screening that deficiencies in Il-4ra, Jak3, and Il-2rg (common
gc) in BC1 cells significantly suppress IL-6 amplifier activation
(Figure S9A). Furthermore, we showed that a certain amount of
Il-4 is expressed in BC1 cells and MEF cells even in steady state
(Figure S9B). Therefore, we hypothesized that IL-4 signaling
might also be involved in IL-6 amplifier activation.
Although positional cloning based on SNP analysis and
genome-wide exome deep-sequencing studies have identified
rare disease-causing mutations in several genes as the single
most important risk factor for various complex diseases and
disorders, recent GWAS analyses have identified numerous
putatively susceptible loci that exert only very small risks
(Manolio et al., 2009), meaning that a large proportion of the
heritability of these diseases cannot be explained by current
genome-wide analyses. It is likely that much of this ‘‘missing
heritability’’ may be accounted for by multiple rare sequence
variants and environmental factors including epigenetic effects
(Hemminki et al., 2011; Manolio et al., 2009; Yang et al., 2010).
Our results suggest that one missing heritability factor might
be a preinflammatory milieu in the affected tissues, as has
been suggested previously by Bertram et al. (2010), Kim et al.
(2009), and Sewell et al. (2009). The accumulation of small func-
tional alterations in such small risk variants in multiple effector
genes including the candidate genes we identified here might
result in activation networks for inflammation, particularly
chronic inflammation, followed by the development of common
diseases and disorders via local activation of the IL-6 amplifier.
In other words, this might be one reason why many genes that
regulate or are expressed after amplifier activation associate
with many human diseases and disorders. Moreover, inflamma-
tion, particularly chronic inflammation, is a general event in many
human diseases and disorders. Thus, the identified genes in this
study, even those without clear SNP-based associations, may
make for potential therapeutic targets against a number of
human diseases.
In conclusion, this studymay offer new clinical targets that can
be used to impair the activation of the IL-6 amplifier in affected
tissues. The approach described here enables rapid identifica-
tion of relevant genes, many of which are likely involved in
inducing the expression of chemokines, proinflammatory cyto-
kines, and their regulators via IL-6-triggered NFkB feedback:
IL-6 amplifier/Inflammation amplifier activation. Based on our
genome-wide functional screen and comparisons with GWAS,
we suggest the inhibition of the epiregulin-ErbB1 signaling
pathway as a potential target for preventing amplifier activation
and the subsequent development of inflammatory diseases956 Cell Reports 3, 946–959, March 28, 2013 ª2013 The Authorsand disorders. Future studies are needed to translate our results
into effective treatments for patients with rheumatoid arthritis,
atherosclerosis, multiple sclerosis, and many other diseases.
EXPERIMENTAL PROCEDURES
Mouse Strains
C57BL/6 mice were purchased from CLEA (Tokyo). The F759 mouse line,
which carries a human gp130 variant (S710L), has been described previously
(Atsumi et al., 2002). All mice were maintained under specific pathogen-free
conditions according to protocols at the Osaka University Medical School.
All animal experiments were performed following the guidelines of the Institu-
tional Animal Care and Use Committees of the Graduate School of Frontier
Biosciences and Graduate School of Medicine (Osaka University).
Clinical Assessment of Arthritis
Mice were inspected and assessed for signs of arthritis as described previ-
ously (Atsumi et al., 2002; Ishihara et al., 2004; Murakami et al., 2011; Ogura
et al., 2008; Sawa et al., 2006). In brief, the severity of the arthritis was deter-
mined based on two bilaterally assessed parameters: (1) swelling in the ankle,
and (2) restricted mobility of the ankle joints. The severity of each parameter
was graded on a scale of 0–3, where 0 indicates no change; 1, mild change;
2, medium change; and 3, severe change. Averages for a single point in one
leg ankle joint from each mouse were used.
Histological Analysis
Joints were fixed in 4% paraformaldehyde, decalcified for 12 hr in Morse’s
solution (22.5% bornyl formate and 10% sodium acid citrate solution), then
12 hr in 4% paraformaldehyde, and embedded in paraffin. Sections were
stained with hematoxylin-eosin (Sawa et al., 2006).
Intracellular Cytokine Staining
The number of Th17 cells in vivo was determined as previously described by
Nishihara et al. (2007). In brief, T cells from spleens were stimulated with phor-
bol myristate acetate and ionomycin (Sigma-Aldrich, Tokyo) in the presence of
GolgiPlug (BD Biosciences, San Jose, CA, USA) for 6 hr. Intracellular IL-17 and
IFN-g were labeled with anti-IL-17 and anti-IFN-g antibodies, respectively,
after surface staining, fixation, and permeabilization.
Antibodies and Reagents
The following antibodies were used for flow cytometry analysis: APC-
conjugated anti-IFN-g (eBioscience, San Diego, CA) and control IgG1k
(eBioscience); FITC-conjugated anti-CD8 (eBioscience), anti-CD11b (Beck-
man Coulter, Brea, CA, USA), anti-CD11c (eBioscience), anti-CD19
(eBioscience), anti-NK1.1 (eBioscience), and anti-I-A/I-E (BioLegend, Tokyo);
PE-conjugated anti-IL-17 (eBioscience), control IgG2a (eBioscience), and
anti-I-A/I-E (BioLegend); and PE-Cy7-conjugated anti-CD4 (BioLegend). The
following antibodies were used for western blotting: anti-phospho-p65
(Ser536, 93H1), anti-phospho-Akt (Ser473, 193H12), anti-phospho-STAT3
(Tyr705), anti-phospho-p44/p42 MAPK(Thr202/Tyr204, E10), anti-Akt, anti-
STAT3 (all from Cell Signaling Technology, Danvers, MA, USA), anti-ERK1
(BD Bioscience), anti-p65 (C-20) (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), HRP-conjugated goat anti-rabbit IgG (H+L) (Southern Biotech, Bir-
mingham, AL, USA), and HRP-conjugated goat anti-mouse IgG (H+L) (Invitro-
gen, Carlsbad, CA, USA). The following antibodies were used for in vivo
neutralization: monoclonal anti-mouse epiregulin antibody (R&D Systems,
Minneapolis) and purified rat IgG (Sigma-Aldrich).
The mission TRC shRNA library, shRNA clones, LPS, puromycin, polybrene,
MOG peptide (33–55), Incomplete Freund’s Adjuvant, protease inhibitor cock-
tail, and phosphatase inhibitor cocktail 2 were obtained from Sigma-Aldrich.
TetraColor One reagent was purchased fromSeikagaku (Tokyo). Mouse Epire-
gulin ELISA Kit, Human soluble IL-6 receptor a, mouse IL-23, human epiregu-
lin, mouse epiregulin, and anti-mouse epiregulin antibody were obtained from
(R&D Systems). Mouse and human IL-17 were obtained from PeproTech
(Rocky Hill, NJ, USA). Human IL-6 was obtained from Toray Industries (Tokyo).
PD153035, PD168393, LY294002, PIK75, and TGX221 were purchased from
Merck (Whitehouse Station, NJ, USA). Gefitinib (brand name, Iressa) was
purchased from Tocris Bioscience (Minneapolis). Epiregulin and IL-6 concen-
trations in patients were measured by a detection kit purchased from Merck
(Tokyo) or Bio-Rad (Tokyo) followed by analysis with a multiplex analysis
device (Bio-Rad) or by ELISA kits (eBioscience).
A control shRNA lentivirus (GCGCGATAGCGCTAATAATTT) and undis-
closed control siRNA were purchased from Sigma-Aldrich. The company
claimed that the sequences were bioinformatically designed to not hit any
transcripts in human, mouse, or rat genomes and that it functions in cells as
expected. BC1 cells infected with a control shRNA lentivirus or a GFP lentivirus
(Sigma-Aldrich) as well as BC1 cells without infection expressed comparable
levels of IL-6 after cytokine stimulation (Figure S9C).
Cells and Stimulation Conditions
A type 1 collagen+ endothelial BC1 cell line (Zhang et al., 1998) was obtained
from Dr. M. Miyasaka (Osaka University). MEF cells were prepared from
C57BL/6 fetuses (13–18 days postcoitus) as described previously by Sawa
et al. (2006). MEF cells were sometimes immortalized via the transfection of
SV40-T antigen. Synovial fibroblasts were prepared as described previously
by Igarashi et al. (2010). HeLa cells were used in the reporter assay.
For stimulation, MEF cells were plated in 96-well plates (1 3 104 cells/well)
and stimulated with human IL-6 (50 ng/ml; Toray Industries) plus human
soluble IL-6 receptor (50 ng/ml; R&D Systems) and/or mouse IL-17
(50 ng/ml; R&D Systems) for 24 or 3 hr after 2 hr of serum starvation. Cell
culture supernatant was collected for ELISAs. In some experiments, cells
were harvested, and total RNA was prepared for real-time PCRs. Human
synovial cell lines were obtained as described previously by Igarashi et al.
(2010).
Genome-wide shRNA Screen
BC1 cells were harvested and counted using a cell counter. The cells were then
cultured on day 1 in a 96-well flat-bottom plate (1,000 cells/well) in 100 ml of
RPMI 1640 containing 10% FBS. The medium was replaced on day 2 with
a RPMI 1640 containing lentivirus carrying candidate-specific shRNA (35 ml
diluted 73), 10% FBS, and 8 mg/ml polybrene. On day 3, 200 ml RPMI 1640
containing 10% FBS and 5 mg/ml puromycin was added to each well. On
day 6, 100 ml RPMI 1640 containing 10% FBS, 100 ng/ml human IL-6,
100 ng/ml human soluble IL-6 receptor, and 50 ng/ml mIL-17 were added to
each well. Supernatants were collected, and ELISAs for mouse IL-6 were
performed. The resulting cells were evaluated for viability on day 7 using
TetraColor One reagent.
Microarray Analysis
W26 cells and human synovial cells were stimulated with 100 ng/ml human
IL-6, 100 ng/ml human soluble IL-6 receptor, and 50 ng/ml mIL-17 or hIL-17
for 3 or 12 hr. Total RNA isolated from the cells was processed into biotinylated
cRNA, which was then hybridized to Affymetrix GeneChips (Tokyo). Raw data
were processed with the MAS5 algorithm for probe-level normalization.
ELISA
IL-6 and epiregulin concentrations in cell culture supernatant were determined
using ELISA kits (BD Bioscience, eBioscience, or R&D Systems).
Flow Cytometry
For cell surface labeling, 106 cells were incubated with fluorescence-
conjugated antibodies for 30 min on ice. The cells then were analyzed with
CyAn flow cytometers (Beckman Coulter). The collected data were analyzed
using FlowJo software (Tree Star, Ashland, OR, USA).
Joint Injections
IL-17 (R&D Systems), IL-6 (Toray Industries), or saline was injected into the
joints as described previously by Maffia et al. (2004). Joints were injected
with a lentivirus carrying shRNA specific for ErbB1 (Egfr), Ereg, and p65
(Rela) (Sigma-Aldrich), a lentivirus carrying a scrambled sequence (Sigma-
Aldrich), or anti-epiregulin antibodies or ErbB1 inhibitors, as described previ-
ously by Maffia et al. (2004).Real-Time PCRs
The 7300 Fast Real-Time PCR System (Applied Biosystems, Tokyo) and SYBR
green PCR Master Mix (Sigma-Aldrich and KAPA Biosystems, Woburn, MA,
USA) were used to quantify levels of target mRNA and Hprt mRNA. Total
RNA was prepared from BC1 cells, MEF cells, and synovial tissues using
a GenElute Mammalian Total RNA kit (Sigma-Aldrich) and DNase I (Sigma-
Aldrich). The PCR primer pairs used are shown in Table S10. The conditions
for real-time PCRs were 40 cycles at 94C for 15 s followed by 40 cycles at
60C for 60 s. The relative mRNA expression levels were normalized to the
levels of Hprt or Gapdh mRNA.
Western Blotting
MEF cells were stimulated by the indicated cytokines and lysed with lysis
buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1% Triton X-100, and 1mM
EDTA) supplemented with protease inhibitor cocktail and phosphatase inhib-
itor cocktail 2 (Sigma-Aldrich). Five to 20 mg of total protein was run on
5%–20% SDS-PAGE (Wako, Tokyo). After transfer to a polyvinylidene fluoride
membrane (Millipore, Billerica, MA, USA), immunoblotting was performed
according to the manufacturer’s protocol.
Luciferase Reporter Assay
A pGL4.32[luc2P/NF-kB-RE/Hygro] vector and pRL-TK vector were tran-
siently cotransfected into HeLa cells and BC1 cells using FuGENE HD Trans-
fection reagent (Promega, Tokyo). Cells were harvested 24 hr after transfection
and stimulated with the indicated reagents for 5 hr. Luciferase activities of total
cell lysates were measured using the Dual-Luciferase Reporter Assay System
(Promega).
Induction of Th17 Cell Differentiation and EAE Development
EAE induction was performed as described previously (Arima et al., 2012;
Ogura et al., 2008).
Mononuclear Cell Isolation from Spinal Cords
Mononuclear cells were isolated from spinal cords after cardiac perfusion with
PBS, as described previously by Sawa et al. (2009).
Human Serum Preparations
Serum was collected from 11 patients with rheumatoid arthritis at Tokyo
Medical and Dental University Hospital, 50 patients with atherosclerosis at
Osaka University Health Care Center, and 21 patients with clinically defined
multiple sclerosis (negative for autoantibody presence) at Osaka University
Hospital. Serum was also collected from 64 healthy subjects at Osaka Univer-
sity Health Care Center. Informed consent was obtained from each patient.
This study was approved by the Ethics Committees of Osaka University
Hospital and Tokyo Medical and Dental University.
Bioinformatic Analysis
Bioinformatic analysis of the candidate genes in screening and the increased
genes in DNA array analysis was done mainly using the GAD at the National
Institute of Aging (http://geneticassociationdb.nih.gov/cgi-bin/index.cgi) for
associations of human diseases and disorders, IPA and OMIM for gene
characters, and IPA for network searching. We declared disease associa-
tions when the GAD reported ‘‘association/Yes,’’ meaning the presence of
statistically positive associations, or when the candidate gene was found to
localize in a relevant chromosomal region based on data from two GWAS
papers by Consortium (2007) and Johnson and O’Donnell (2009).
Statistical Analysis
Student’s t tests (one or two tailed) were used for the statistical analyses of
differences between groups. A p value of <0.1 was used as a cutoff for the
bioinformatic results including Tables 1 and 2 but p < 0.05 for the biology
experiments including Figures 1, 2, 3, 4, and 5.
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